Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice

BACKGROUND: Acromegaly patients managed on Somatostatin receptor ligands (SRLs), the most common first-line pharmacotherapy for acromegaly, may still experience acromegaly symptoms such as headache, sweating, fatigue, soft tissue swelling, and joint pain, even those with normal IGF-1. Additionally,...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:BMC Endocr Disord
Asıl Yazarlar: Geer, Eliza B., Sisco, Jill, Adelman, Daphne T., Ludlam, William H., Haviv, Asi, Liu, Shuqian, Mathias, Susan D., Gelbaum, Dana, Shi, Lizheng
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2020
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7393879/
https://ncbi.nlm.nih.gov/pubmed/32736547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12902-020-00595-4
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller